SAN FRANCISCO, May 2, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2024 on Thursday, May 9, 2024, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. The press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page a ...

Table of Contents w UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number: 0-24006 NEKTAR THERAPEUTICS (Exact name of registrant as specified in its charter) Delaware 94-3134940 (State or other jurisdi ...

Nektar Therapeutics (NASDAQ:NKTR) Q4 2023 Earnings Conference Call March 4, 2024 5:00 PM ET Company Participants Vivian Wu - Director, Investor Relations and Corporate Affairs Howard Robin - President and Chief Executive Officer Jonathan Zalevsky - Chief Research & Development Officer Sandra Gardiner - Chief Financial Officer Mary Tagliaferri - Chief Medical Officer Conference Call Participants Cheng Li - Oppenheimer & Co. Inc. Kambiz Yazdi - Jefferies Group LLC Jessica Fye - JPMorgan Chase & Co. Julian Har ...

Exhibit 99.1 Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results SAN FRANCISCO, March 4, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2023. Cash and investments in marketable securities at December 31, 2023, were $329.4 million as compared to $505.0 million at December 31, 2022. Nektar's cash and marketable securities are expected to support strategic development activities and oper ...

Nektar Therapeutics (NASDAQ:NKTR) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants Vivian Wu - Director, IR and Corporate Affairs Howard Robin - President and CEO Jonathan Zalevsky - Chief, Research and Development Mary Tagliaferri - Chief Medical Officer Jennifer Ruddock - Chief Business Officer Conference Call Participants Jay Olson - Oppenheimer Charles Ferranti - Goldman Sachs Operator Good day and thank you for standing by. Welcome to the Nektar Therapeutics Third Quart ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006 NEKTAR THERAPEUTICS (Exact name of registrant as specified in its charter) (State or other jurisdiction of inco ...

Nektar Therapeutics (NASDAQ:NKTR) Q2 2023 Earnings Conference Call August 8, 2023 5:00 PM ET Company Participants Vivian Wu - Director, Investor Relations and Corporate Affairs Howard Robin - President and CEO Dr. Jonathan Zalevsky - Chief, Research and Development Dr. Mary Tagliaferri - Chief Medical Officer Jennifer Ruddock - Chief Business Officer Sandra Gardiner - Acting Chief Financial Officer Conference Call Participants Cheng Li - Oppenheimer & Co. Inc. Mara Goldstein - Mizuho Kambiz Yazdi - Jefferie ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________________________________________________________________ FORM 10-Q _______________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Comm ...

Nektar Therapeutics (NASDAQ:NKTR) Q3 2021 Earnings Conference Call November 4, 2021 5:00 PM ET Company Participants Jennifer Ruddock - Senior Vice President, Strategy and Corporate Affairs Howard Robin - President and Chief Executive Officer Dimitry Nuyten - Senior Vice President and Chief Medical Officer Jonathan Zalevsky - Chief Research and Development Officer Gil Labrucherie - Chief Operating Officer and Chief Financial Officer Conference Call Participants Chris Shibutani - Goldman Sachs Jay Olson - Opp ...

Table of Contents Commission File Number: 0-24006 _______________________________________________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 NEKTAR THERAPEUTICS _______________________________________________________________________ FORM 10-Q _______________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 (Exact n ...